SGLT2 inhibitors like empagliflozin and canagliflozin reduce senescent cell burden and modulate the senescence-associated secretory phenotype (SASP), suggesting genuine senotherapeutic properties. These drugs induce metabolic states resembling caloric restriction and ketosis while improving mitochondrial function and cellular stress resistance. The anti-aging potential extends far beyond their original glucose-lowering mechanism. This represents a significant development in aging research because repurposing existing cardiovascular drugs for longevity applications offers unprecedented safety profiles and regulatory pathways. Unlike experimental senolytic compounds still in development, SGLT2 inhibitors already have decades of human safety data and are widely prescribed. The mechanistic overlap with proven longevity interventions—caloric restriction mimetics, mitochondrial enhancement, and senescent cell clearance—positions these drugs as potential first-generation clinical anti-aging therapeutics. However, the evidence remains largely preclinical, and human longevity trials would require decades to complete. The real breakthrough lies in demonstrating that established medications can target fundamental aging mechanisms, potentially accelerating the translation of aging research into clinical practice for healthy adults seeking to extend healthspan.